Industry News

  • Deerfield, Ill., U.S., April 28, and Osaka, Japan, April 29, 2015 – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that they have reached an agreement expected to resolve the vast majority of ACTOS (pioglitazone HCl) product liability lawsuits pending against Takeda in the U.S. Takeda will take a $2.7 billion charge against earnings in the fourth quarter of fiscal year 2014 to cover the settlement and the costs associated with defending remaining cases and for other related litigation. The settlement will become effective if 95 percent of current litigants and claimants opt into the settlement. Once that threshold is achieved, Takeda will pay $2.37 billion into a settlement fund. However, that figure will rise to $2.4 billion if 97 percent or more of the current litigants and claimants opt to participate in the settlement.

  • European Commission has granted marketing authorization in Europe for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults.

  • (Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, today announced that its Contract Research subsidiary Syngene International Ltd (“Syngene”) has filed the Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on April 22, 2015, seeking approval for an Initial Public Offering (IPO). This is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene. Biocon along with its subsidiary Biocon Research Limited (BRL) currently holds an 84.5% equity stake in Syngene.

  • Novo Nordisk, a world leader in insulin and diabetes care,  has launched Saxenda (liraglutide 3 mg), the first glucagon-like peptide-1 (GLP-1) receptor agonist the United States.  Saxenda is a drug used to treat obesity.  Saxenda has approved in the US, EU and Canada.

  • 28 April 2015
    Launch Avycaz by Actavis in US markets to treat cIAI and complicated urinary tract infections

    In the United States, Actavis plc, global pharmaceutical company, has launched Avycaz (ceftazidime-avibactam) to treat adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. Avycaz should be reserved for use in patients who have limited or no alternative treatment options.

  • Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N.V.,  has launched generic sofosbuvir 400 mg tablets under the brand name MyHep in India. The product is used for the treatment of chronic hepatitis C,which is a long-lasting infection with the hepatitis C virus. Chronic hepatitis C is a blood-borne infectious disease that affects more than 100 million people in the developing world, including approximately 12 million people in India.

  • Mauna Kea Technologies, inventor of Cellvizio, the multidisciplinary confocal laser endomicroscopy platform, has received regulatory approval from COFEPRIS (Comisión Federal Para la Protección contra Riesgos Sanitarios), the Mexican health authority, for the commercialization of Cellvizio.. Mauna Kea Technologies is now able to implement its marketing strategy with its partner, Endomédica, a company specialized in the fields of interventional endoscopy, gastroenterology, urology and surgery since 1986.

Subscribe to Industry News